Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

More on RSV and Ribavirin

D L Jury

    Pediatric Nursing
    |January 1, 1993
    PubMed
    Summary

    Ribavirin, used to treat respiratory syncytial virus (RSV) in infants, may pose risks during pregnancy. However, its benefits outweigh risks, making its elimination unjustified for caregivers.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Leading the change.

    Clinical nurse specialist CNS·1996
    See all related articles

    Area of Science:

    • Pharmacology
    • Teratology
    • Pediatric Infectious Diseases

    Background:

    • Environmental exposure to Ribavirin in rodents, rabbits, and hamsters has raised concerns regarding teratogenic potential.
    • Ribavirin is a critical medication for treating severe respiratory syncytial virus (RSV) infections in infants and children.

    Purpose of the Study:

    • To evaluate the risks and benefits of Ribavirin use in the context of potential caregiver exposure.
    • To address concerns about teratogenicity and inform clinical practice regarding Ribavirin therapy for RSV.

    Main Methods:

    • Review of existing literature on Ribavirin teratogenicity in animal models.
    • Assessment of the clinical efficacy and safety data for Ribavirin in pediatric RSV treatment.
    • Risk-benefit analysis considering both fetal and patient outcomes.

    Main Results:

    • Animal studies indicate teratogenic potential of Ribavirin.
    • Ribavirin demonstrates significant efficacy in treating life-threatening RSV infections in infants and young children.
    • Eliminating Ribavirin solely based on caregiver exposure concerns is not scientifically or ethically supported.

    Conclusions:

    • The proven efficacy of Ribavirin in treating severe RSV in infants justifies its continued use.
    • Caregiver exposure risks must be managed, but should not preclude essential treatment for pediatric patients.
    • Clinical guidelines should balance teratogenicity concerns with the life-saving benefits of Ribavirin for RSV.

    Related Experiment Videos